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http://dx.doi.org/10.1016/j.ccr.2012.06.032SUMMARYRecurrent somatic ASXL1 mutations occur in patients with myelodysplastic syndrome, myeloproliferative
neoplasms, and acute myeloid leukemia, and are associated with adverse outcome. Despite the genetic
and clinical data implicating ASXL1 mutations in myeloid malignancies, the mechanisms of transformation
by ASXL1 mutations are not understood. Here, we identify that ASXL1 mutations result in loss of polycomb
repressive complex 2 (PRC2)-mediated histone H3 lysine 27 (H3K27) tri-methylation. Through integration of
microarray data with genome-wide histonemodification ChIP-Seq data, we identify targets of ASXL1 repres-
sion, including the posterior HOXA cluster that is known to contribute to myeloid transformation. We demon-
strate that ASXL1 associates with the PRC2, and that loss of ASXL1 in vivo collaborates with NRASG12D to
promote myeloid leukemogenesis.INTRODUCTION
Recent genome-wide and candidate-gene discovery efforts
have identified a series of novel somatic genetic alterations in
patients with myeloid malignancies with relevance to pathogen-Significance
Mutations in genes involved in modification of chromatin have
malignancies. Here, we demonstrate a specific role for ASXL1,
malignancies, in polycomb repressive complex 2 (PRC2)-media
loss-of-function mutations in myeloid malignancies result in lo
genic target genes. Our data provide insight into how ASXL1m
regulation of Polycomb-mediated gene silencing. This approac
can be used to elucidate the function of mutations in epigenet
180 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.esis, prognostication, and/or therapy. Notably, these include
mutations in genes with known or putative roles in the epigenetic
regulation of gene transcription. One such example is the muta-
tions in the gene Addition of sex combs-like 1 (ASXL1), which
is mutated in z15%–25% of patients with myelodysplasticrecently been identified in patients with leukemias and other
a putative epigenetic modifier frequently mutated in myeloid
ted transcriptional repression in hematopoietic cells.ASXL1
ss of PRC2-mediated gene repression of known leukemo-
utations contribute to myeloid transformation through dys-
h also demonstrates how epigenomic and functional studies
ic modifiers in malignant transformation.
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ASXL1 Loss Inhibits PRC2 in Myeloid Leukemiasyndrome and z10%–15% of patients with myeloproliferative
neoplasms and acute myeloid leukemia (Abdel-Wahab et al.,
2011; Bejar et al., 2011; Gelsi-Boyer et al., 2009). Clinical studies
have consistently indicated that mutations in ASXL1 are associ-
ated with adverse survival in myelodysplastic syndrome and
acute myeloid leukemia (Bejar et al., 2011; Metzeler et al.,
2011; Pratcorona et al., 2012; Thol et al., 2011).
ASXL1 is the human homolog of Drosophila Additional sex
combs (Asx). Asx deletion results in a homeotic phenotype char-
acteristic of both Polycomb (PcG) and Trithorax group (TxG)
gene deletions (Gaebler et al., 1999), which led to the hypothesis
that Asx has dual functions in silencing and activation of
homeotic gene expression. In addition, functional studies in
Drosophila suggested that Asx encodes a chromatin-associated
protein with similarities to PcG proteins (Sinclair et al., 1998).
More recently, it was demonstrated that Drosophila Asx forms
a complex with the chromatin deubiquitinase Calypso to form
the Polycomb-repressive deubiquitinase (PR-DUB) complex,
which removes monoubiquitin from histone H2A at lysine 119.
The mammalian homolog of Calypso, BAP1, directly associates
with ASXL1, and the mammalian BAP1-ASXL1 complex was
shown to possess deubiquitinase activity in vitro (Scheuermann
et al., 2010).
The mechanisms by which ASXL1 mutations contribute to
myeloid transformation have not been delineated. A series of
in vitro studies in non-hematopoietic cells have suggested
a variety of activities for ASXL1, including physical cooperativity
with HP1a and LSD1 to repress retinoic acid-receptor activity
and interaction with peroxisome proliferator-activated receptor
gamma (PPARg) to suppress lipogenesis (Cho et al., 2006; Lee
et al., 2010; Park et al., 2011). In addition, a recent study using a
gene-trap model reported that constitutive disruption of Asxl1
results in significant perinatal lethality; however, the authors
did not note alterations in stem/progenitor numbers in surviving
Asxl1 gene trap mice (Fisher et al., 2010a, 2010b). Importantly,
the majority of mutations in ASXL1 occur as nonsense mutations
and insertions/deletions proximal or within the last exon prior
to the highly conserved plant homeo domain. It is currently
unknown whether mutations in ASXL1 might confer a gain-of-
function due to expression of a truncated protein, or whether
somatic loss of ASXL1 in hematopoietic cells leads to specific
changes in epigenetic state, gene expression, or hematopoietic
functional output. The goals of this study were to determine the
effects of ASXL1 mutations on ASXL1 expression as well as the
transcriptional and biological effects of perturbations in ASXL1
which might contribute toward myeloid transformation.
RESULTS
ASXL1 Mutations Result in Loss of ASXL1 Expression
ASXL1 mutations in patients with myeloproliferative neoplasms,
myelodysplastic syndrome, and acute myeloid leukemia most
commonly occur as somatic nonsense mutations and inser-
tion/deletion mutations in a clustered region adjacent to the
highly conserved PHD domain (Abdel-Wahab et al., 2011;
Gelsi-Boyer et al., 2009). To assess whether these mutations
result in loss of ASXL1 protein expression or in expression of
a truncated isoform, we performed western blots using N- and
C-terminal anti-ASXL1 antibodies in a panel of human myeloidleukemia cell lines and primary acute myeloid leukemia samples,
which are wild-type or mutant for ASXL1. We found that myeloid
leukemia cells with homozygous frameshift/nonsense mutations
inASXL1 (NOMO1 and KBM5) have no detectable ASXL1 protein
expression (Figure 1A). Similarly, leukemia cells with heterozy-
gous ASXL1 mutations have reduced or absent ASXL1 protein
expression. Western blot analysis of ASXL1 using an N-terminal
anti-ASXL1 antibody in primary acute myeloid leukemia samples
wild-type and mutant for ASXL1 revealed reduced/absent full-
length ASXL1 expression in samples with ASXL1 mutations
compared to ASXL1 wild-type samples (Figure S1A available
online). Importantly, we did not identify truncated ASXL1 protein
products in mutant samples using N- or C-terminal directed anti-
bodies in primary acute myeloid leukemia samples or leukemia
cell lines. Moreover, expression of wild-type ASXL1 cDNA or
cDNA constructs bearing leukemia-associated mutant forms of
ASXL1 revealed reduced stability of mutant forms of ASXL1 rela-
tive to wild-type ASXL1, with more rapid degradation of mutant
ASXL1 isoforms following cycloheximide exposure (Figure S1B).
These data are consistent with ASXL1 functioning as a tumor
suppressor with loss of ASXL1 protein expression in leukemia
cells with mutant ASXL1 alleles.
ASXL1 Knockdown in Hematopoietic Cells Results
in Upregulated HOXA Gene Expression
Given that ASXL1 mutations result in loss of ASXL1 expression,
we investigated the effects of ASXL1 knockdown in primary
hematopoietic cells. We used a pool of small interfering RNAs
(siRNA) to perform knockdown of ASXL1 in primary human
CD34+ cells isolated from umbilical cord blood. ASXL1 knock-
down was performed in triplicate and confirmed by qRT-PCR
analysis (Figure 1B), followed by gene-expression microarray
analysis. Gene-set enrichment analysis (GSEA) of thismicroarray
data revealed a significant enrichment of genes found in a previ-
ously described gene expression signature of leukemic cells
from bone marrow of MLL-AF9 knock-in mice (Kumar et al.,
2009), as well as highly significant enrichment of a gene signa-
ture found in primary human cord blood CD34+ cells expressing
NUP98-HOXA9 (Figure S1C and Table S1) (Takeda et al., 2006).
Specifically, we found that ASXL1 knockdown in human primary
CD34+ cells resulted in increased expression of 145 genes out of
the 279 genes, which are overexpressed in the MLL-AF9 gene
expression signature (p < 0.05, FDR < 0.05). These gene expres-
sion signatures are characterized by increased expression of
posterior HOXA cluster genes, including HOXA5-9.
In order to ascertain whether loss of ASXL1 was associated
with similar transcriptional effects in leukemia cells, we per-
formed short hairpin RNA (shRNA)-mediated stable knockdown
of ASXL1 in the ASXL1-wild-type human leukemia cell lines
UKE1 (Figures 1C and 1D) and SET2 (Figure 1D) followed by
microarray and qRT-PCR analysis. Gene expression analysis in
UKE-1 cells expressing ASXL1 shRNA compared to control cells
revealed significant enrichment of the same HOXA gene expres-
sion signatures as were seen with ASXL1 knockdown in CD34+
cells (Figure 1C and Table S2). Upregulation of 50 HOXA genes
was confirmed by qRT-PCR in UKE1 (Figure 1D) cells and by
western blot analysis (Figure 1D) in SET2 cells expressing
ASXL1 shRNA compared to control. Quantitative mRNA profiling
(Nanostring nCounter) of the entire HOXA cluster revealedCancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc. 181
Figure 1. Leukemogenic ASXL1Mutations Are Loss-of-Function Mutations and ASXL1 Loss Is Associated with Upregulation of HOXA Gene
Expression
(A) Characterization of ASXL1 expression in leukemia cells with nonsense mutations in ASXL1 reveals loss of ASXL1 expression at the protein level in cells with
homozygous ASXL1 mutations as shown by western blotting using N- and C-terminal anti-ASXL1 antibodies.
(B) Displayed are the ASXL1-mutant cell line lines NOMO1 (homozygous ASXL1 R639X), K562 (heterozygous ASXL1 Y591Y/X), and KBM5 (homozygous ASXL1
G710X) and a panel ofASXL1-wild-type cell lines.ASXL1 siRNA in human primary CD34+ cells form cord blood results in upregulation ofHOXA5 andHOXA9with
ASXL1 knockdown (KD) as revealed by quantitative real-time PCR (qRT-PCR) analysis.
(C and D) Stable KD of ASXL1 in ASXL1-wild-type transformed human myeloid leukemia UKE1 cells (as shown by western blot) followed by GSEA reveals
significant enrichment of gene sets characterized by upregulation of 50 HOXA genes (C) as was confirmed by qRT-PCR (D). Statistical significance is indicated in
(D) by the p value and false-discovery rate (FDR). Similar upregulation of HOXA9 is seen by the western blot following stable ASXL1 KD in the ASXL1-wild-type
human leukemia SET2 cells.
Error bars represent standard deviation of expression relative to control. See also Figure S1 and Tables S1 and S2.
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ASXL1 Loss Inhibits PRC2 in Myeloid Leukemiaupregulation of multiple HOXAmembers, including HOXA5, 7, 9,
and 10, in SET2 cells with ASXL1 knockdown compared to
control cells (Figure S1D). These results indicate consistent
upregulation of HOXA gene expression following ASXL1 loss in
multiple hematopoietic contexts.
ASXL1 Forms a Complex with BAP1 in Leukemia Cells,
but BAP1 Loss Does Not Upregulate HoxA Gene
Expression in Hematopoietic Cells
Mammalian ASXL1 forms a protein complex in vitro with the
chromatin deubiquitinase BAP1, which removes monoubiquitin
from histone H2A at lysine 119 (H2AK119) (Scheuermann et al.,
2010). In Drosophila loss of either Asx or Calypso resulted in
similar effects on genome-wide H2AK119 ubiquitin levels and
on target gene expression. Recent studies have revealed recur-
rent germline and somatic loss-of-function BAP1 mutations in
mesothelioma and uveal melanoma (Bott et al., 2011; Harbour
et al., 2010; Testa et al., 2011). However, we have not identified
BAP1mutations in patients with myeloproliferative neoplasms or182 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.acute myeloid leukemia (O.A.-W., J.P.P., and R.L.L., unpub-
lished data). Co-immunopreciptation studies revealed an asso-
ciation between ASXL1 and BAP1 in human myeloid leukemia
cells wild-type for ASXL1 but not in those cells mutant for
ASXL1 due to reduced/absent ASXL1 expression (Figure 2A).
Immunoprecipitation of FLAG-tagged wild-type ASXL1 and
FLAG-tagged leukemia-associated mutant forms of ASXL1 re-
vealed reduced interaction between mutant forms of ASXL1
and endogenous BAP1 (Figure S2A). Despite these findings,
BAP1 knockdown did not result in upregulation of HOXA5 and
HOXA9 in UKE1 cells, although a similar extent of ASXL1 knock-
down in the same cells reproducibly increased HOXA5 and
HOXA9 expression (Figure 2B). We obtained similar results
with knockdown of Asxl1 or Bap1 in the Ba/F3 murine hemato-
poietic cell line (Figure 2C). In Ba/F3 cells, knockdown of Asxl1
resulted in upregulated Hoxa9 gene expression commensurate
with the level of Asxl1 downregulation, whereas knockdown of
Bap1 does not impact Hoxa expression (Figure 2C). ASXL1
knockdown in SET-2 cells failed to reveal an effect of ASXL1
Figure 2. ASXL1 and BAP1 Physically
Interact in Human Hematopoietic Cells but
BAP1 Loss Does Not Result in Increased
HoxA Gene Expression
(A) Immunoprecipitation of BAP1 in a panel of
ASXL1-wild-type and mutant human myeloid
leukemia cells reveals co-association of ASXL1
and BAP1.
(B) Cells with heterozygous or homozygous
mutations inASXL1with reduced or absent ASXL1
expression have minimal interaction with BAP1
in vitro. BAP1 knockdown in the ASXL1/BAP1
wild-type human leukemia cell line UKE1 fails to
alter HOXA gene expression. In contrast, stable
knockdown of ASXL1 in the same cell type results
in a significant upregulation of HOXA9.
(C) Similar results are seen with knockdown of
Asxl1 or Bap1 in murine precursor-B lymphoid Ba/
F3 cells.
Error bars represent standard deviation of ex-
pression relative to control. See also Figure S2.
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ASXL1 Loss Inhibits PRC2 in Myeloid Leukemialoss on H2AK119Ub levels as assessed by western blot of puri-
fied histones from shRNA control and ASXL1 knockdown cells
(Figure S2B). By contrast, SET2 cells treated with MG132
(25 mM) had a marked decrease in H2AK119Ub, as has been
previously described (Dantuma et al., 2006). These data suggest
that ASXL1 loss contributes to myeloid transformation through
a BAP1-independent mechanism.
Loss of ASXL1 Is Associated with Global Loss
of H3K27me3
The results described above led us to hypothesize that ASXL1
loss leads to BAP1-independent effects on chromatin state
and on target gene expression. To assess the genome-wide
effects of ASXL1 loss on chromatin state, we performed chro-Cancer Cell 22, 180–193matin immunoprecipitation followed by
next generation sequencing (ChIP-seq)
for histone modifications known to be
associated with PcG [histone H3 lysine
27 trimethylation (H3K27me3)] or TxG
activity [histone H3 lysine 4 trimethylation
(H3K4me3)] in UKE1 cells expressing
empty vector or two independent vali-
dated shRNAs for ASXL1. ChIP-Seq data
analysis revealed a significant reduction
in genome-wide H3K27me3 transcrip-
tional start site occupancy with ASXL1
knockdown compared to empty vector
(p = 2.2 3 1016; Figure 3A). Approxi-
mately 20% of genes (n = 4,686) were
initially marked by H3K27me3 in their
promoter regions (defined as 1.5 kb
downstream and 0.5 kb upstream of
the transcriptional start site). Among
these genes, 27% had a 2-fold reduc-
tion in H3K27me3 (n = 1,309) and
66% had a 1.5-fold reduction in
H3K27me3 (n = 3,092), respectively,
upon ASXL1 knockdown. No significanteffect was seen on H3K4me3 transcriptional start site occu-
pancy with ASXL1 depletion (Figure 3A). We next evaluated
whether loss of ASXL1 might be associated with loss of
H3K27me3 globally by performing western blot analysis on
purified histones from UKE1 cells transduced with empty
vector or shRNAs for ASXL1 knockdown. This analysis revealed
a significant decrease in global H3K27me3 with ASXL1 loss
(Figure 3B), despite preserved expression of the core poly-
comb repressive complex 2 (PRC2) members EZH2, SUZ12,
and EED. Similar effects on total H3K27me3 levels were
seen following Asxl1 knockdown in Ba/F3 cells (Figure S3A).
These results demonstrate that ASXL1 depletion leads to a
marked reduction in genome-wide H3K27me3 in hematopoietic
cells., August 14, 2012 ª2012 Elsevier Inc. 183
Figure 3. ASXL1 Loss Is Associated with Loss of H3K27me3 and with Increased Expression of Genes Poised for Transcription
(A) ASXL1 loss is associated with a significant genome-wide decrease in H3K27me3 as illustrated by box plot showing the 25th, 50th, and 75th percentiles for
H3K27me3 and H3K4me3 enrichment at transcription start sites in UKE1 cells treated with an empty vector or shRNAs directed against ASXL1. The whiskers
indicate the most extreme data point less than 1.5 interquartile range from box and the red bar represents the median.
(B) Loss of ASXL1 is associated with a global loss of H3K27me3without affecting PRC2 component expression as shown bywestern blot of purified histones from
cells with UKE1 knockdown and western blot for core PRC2 component in whole cell lysates from ASXL1 knockdown UKE1 cells.
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ASXL1 Loss Inhibits PRC2 in Myeloid LeukemiaDetailed analysis of ChIP-seq data revealed that genomic
regions marked by large H3K27me3 domains in control cells
displayed more profound loss of H3K27me3 upon loss of
ASXL1. Genome-wide analysis of the ChIP-Seq data from
control and ASXL1 shRNA treated cells revealed that the sites
that lose H3K27me3 in the ASXL1 knockdown cells were on
average 6.6 kb in length, while the sites that maintained
H3K27me3 were on average 3.1 kb in length (p < 1016) (Fig-
ure S3B). This is visually illustrated by the reduction in
H3K27me3 at the posterior HOXA cluster (Figure 3C) and at
the HOXB and HOXC loci (Figure S3C). The association of
ASXL1 loss with loss of H3K27me3 abundance at the HOXA
locus was confirmed by ChIP for H3K27me3 in control and
ASXL1 knockdown cells followed by qPCR (ChIP-qPCR) across
the HOXA locus (Figure 3D). ChIP-qPCR in control and knock-
down cells revealed a modest increase in H2AK119Ub with
ASXL1 loss at the HOXA locus (Figure 3D), in contrast to the
more significant reduction in H3K27me3. In contrast to the
large decrease in H3K27me3 levels at the HOXA locus with
ASXL1 knockdown, a subset of loci had much less significant
reduction in H3K27me3, in particular at loci whose promoters
were marked by sharp peaks of H3K27me3 (Figure S3D). Inter-
section of gene expression and ChIP-Seq data revealed that
genes overexpressed in ASXL1 knockdown cells were simulta-
neously marked with both activating (H3K4me3) and repressive
(H3K27me3) domains in control cells (Figures 3E and 3F). This
finding suggests that the transcriptional repression mediated
by ASXL1 in myeloid cells is most apparent at loci poised for
transcription with bivalent chromatin domains. Indeed, the
effects of ASXL1 loss on H3K27me3 occupancy were most
apparent at genes whose promoters were marked by the dual
presence of H3K27me3 and H3K4me3 (Figure 3F). We cannot
exclude the possibility that H3K4me3 and H3K27me3 exist in
different populations within the homogeneous cell lines being
studied, but the chromatin and gene expression data are
consistent with an effect of ASXL1 loss on loci with bivalent
chromatin domains (Bernstein et al., 2006; Mikkelsen et al.,
2007).Enforced Expression of ASXL1 in Leukemic Cells
Results in Suppression of HOXA Gene Expression,
a Global Increase in H3K27me3, and Growth
Suppression
We next investigated whether reintroduction of wild-type
ASXL1 protein could restore H3K27me3 levels in ASXL1
mutant leukemia cells. We stably expressed wild-type ASXL1
in NOMO1 and KBM5 cells, homozygous ASXL1 mutant human(C) Loss of H3K27me3 is evident at the HOXA locus as shown by ChIP-Seq prom
shRNA knockdown of ASXL1.
(D) H3K27me3ChIP-Seq promoter track signals fromHOXA5 toHOXA13 in UKE1
primers used in ChIP-quantitative PCR (ChIP-qPCR) validation. ChIP for H3K27
ASXL1 knockdown confirms a significant decrease in H3K27me3 at the HOXA
H2AK119Ub levels at the same primer locations.
(E) Integrating gene-expression data with H3K27me3/H3K4me3ChIP-Seq identifi
in gene expression following ASXL1 loss at loci normally marked by the simultan
(F) Loss of H3K27me3 is seen at promoters normally marked by the presence of H
the control state.
See also Figure S3.leukemia cell lines, which do not express ASXL1 protein
(Figure 4A and Figure S4A). ASXL1 expression resulted in a
global increase in H3K27me3 as assessed by histone western
blot analysis (Figure 4A). Liquid chromotography/mass spec-
trometry of purified histones in NOMO1 cells expressing
ASXL1 confirmed a 2.5-fold increase in trimethylated H3K27
peptide and significant increases in dimethylated H3K27 in
NOMO1 cells expressing ASXL1 compared to empty vector
control (Figure 4B). ASXL1 add-back resulted in growth sup-
pression (Figure 4C) and in decreased HOXA gene expression
in NOMO1 cells (Figure 4D). ASXL1 add-back similarly resulted
in decreased expression of HOXA target genes in KBM5 cells
(Figures S4A and S4B). ChIP-qPCR revealed a strong enrich-
ment in ASXL1 binding at the HOXA locus in NOMO1 cells
expressing ASXL1, demonstrating that the HOXA locus is
a direct target of ASXL1 in hematopoietic cells (Figure 4E).ASXL1 Loss Leads to Exclusion of H3K27me3 and EZH2
from the HoxA Cluster Consistent with a Direct Effect of
ASXL1 on PRC2 Recruitment
We next investigated whether the effects of ASXL1 loss on
H3K27me3 was due to inhibition of PRC2 recruitment to
specific target loci. ChIP-qPCR for H3K27me3 in SET2
cells with ASXL1 knockdown or control revealed a loss of
H3K27me3 enrichment at the posterior HoxA locus with
ASXL1 knockdown (Figures 5A and 5B). We observed a
modest, variable increase in H3K4me3 enrichment at the
HOXA locus with ASXL1 depletion in SET2 cells (Figure 5C).
We similarly assessed H3K27me3 enrichment in primary bone
marrow leukemic cells from acute myeloid leukemia patients,
wild-type and mutant for ASXL1, which likewise revealed de-
creased H3K27me3 enrichment across the HOXA cluster in
primary acute myeloid leukemia samples with ASXL1
mutations compared to ASXL1-wild-type acute myeloid leu-
kemia samples (Figure 5D).
Given the consistent effects of ASXL1 depletion on
H3K27me3 abundance at the HOXA locus, we then evaluated
the occupancy of EZH2, a core PRC2 member, at the HoxA
locus. ChIP-Seq for H3K27me3 in native SET2 and UKE1 cells
identified that H3K27me3 is present with a dome-like enrich-
ment pattern at the 50 end of the posterior HOXA cluster (Fig-
ure 5A); ChIP-qPCR revealed that EZH2 is prominently enriched
in this same region in parental SET2 cells (Figure 5E). Impor-
tantly, ASXL1 depletion resulted in loss of EZH2 enrichment at
the HOXA locus (Figure 5E), suggesting that ASXL1 is required
for EZH2 occupancy and for PRC2-mediated repression of the
posterior HOXA locus.oter track signals across the HOXA locus in UKE1 cells treated with an EV or
cells treatedwith shRNA control or one of 2 anti-ASXL1 shRNAswith location of
me3 and H2AK119Ub followed by ChIP-qPCR in cells treated with control or
locus with ASXL1 knockdown but minimal effects of ASXL1 knockdown on
es a significant correlation between alterations in chromatin state and increases
eous presence of H3K27me3 and H3K4me3 in control cells.
3K27me3 alone or at promoters co-occupied by H3K27me3 and H3K4me3 in
Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc. 185
Figure 4. Expression of ASXL1 in ASXL1-Null Leukemic Cells Results in Global Increase in H3K27me2/3, Growth Suppression, and Suppres-
sion of HoxA Gene Expression
(A and B) ASXL1 expression in ASXL1 null NOMO1 cells is associated with a global increase in H3K27me3 as detected by western blot of purified histones (A) as
well as by quantitative liquid-chromatography/mass spectrometry of H3 peptides from amino acids 18–40 (B) (arrows indicate quantification of H3K27me1/2/3).
(C) ASXL1 overexpression results in growth suppression in 7-day growth assay performed in triplicate.
(D) Overexpression of ASXL1 was associated with a decrement in posteriorHoxA gene expression in NOMO1 cells as shown by qRT-PCR forHOXA5, 6, 7, and 9.
(E) This downregulation in HOXA gene expression was concomitant with a strong enrichment of ASXL1 at the loci of these genes as shown by chromatin
immunoprecipitation of ASXL1 followed by quantitative PCR with BCRRP1 as a control locus.
Error bars represent standard deviation of target gene expression relative to control. See also Figure S4.
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ASXL1 Loss Inhibits PRC2 in Myeloid LeukemiaASXL1 Physically Interacts with Members of the PRC2
in Human Myeloid Leukemic Cells
Given that ASXL1 localizes to PRC2 target loci and ASXL1 deple-
tion leads to loss of PRC2 occupancy and H3K27me2, we inves-
tigated whether ASXL1 might physically interact with the
PRC2 complex in hematopoietic cells. Co-immunoprecipitation
studies using an anti-FLAG antibody in HEK293T cells express-
ing empty vector, hASXL1-FLAG alone, or hASXL1-FLAG
plus hEZH2 cDNA revealed a clear co-immunoprecipitation of
FLAG-ASXL1 with endogenous EZH2 and with ectopically ex-
pressed EZH2 (Figure 6A). Similarly, co-immuniprecipitation of
FLAG-ASXL1 revealed physical association between ASXL1
and endogenous SUZ12 in 293T cells (Figure 6A). Immunopre-
cipitations were performed in the presence of benzonase to
ensure that the protein-protein interactions observed were
DNA-independent (Figure 6B) (Muntean et al., 2010).We then as-
sessed whether endogenous ASXL1 formed a complex with186 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.PRC2 members in hematopoietic cells. We performed IP for
EZH2 or ASXL1 followed by western blotting for partner proteins
in SET2 and UKE1 cells, which are wild-type for ASXL1, SUZ12,
EZH2, and EED. These co-immunoprecipitation assays all re-
vealed a physical association between ASXL1 and EZH2 in
SET2 (Figure 6B) and UKE1 cells (Figure S5). By contrast, immu-
noprecipitation of endogenous ASXL1 did not reveal evidence
of protein-protein interactions between ASXL1 and BMI1 (Fig-
ure S5). Likewise, immunoprecipitation of BMI1 enriched for
PRC1 member RING1A, but failed to enrich for ASXL1, suggest-
ing a lack of interaction between ASXL1 and the PRC1 repressive
complex (Figure 6C).
ASXL1 Loss Collaborates with NRasG12D In Vivo
We and others previously reported that ASXL1 mutations are
most common in chronic myelomonocytic leukemia and
frequently co-occur with N/K-Ras mutations in chronic
Figure 5. ASXL1 Loss Is Associated with
Loss of PRC2 Recruitment at the HOXA
Locus
(A) Chromatin-immunoprecipitation (ChIP) for
H3K27me3 and H3K4me3 followed by next-
generation sequencing reveals the abundance
and localization of H3K27me3 and H3K4me3 at
the HoxA locus in SET2 cells.
(B and C) ChIP for H3K27me3 (B) and H3K4me3
(C) followed by quantitative PCR (qPCR) across
the 50 HOXA locus in SET2 cells treated with an
empty vector or stable knockdown of ASXL1
reveals a consistent downregulation of H3K27me3
across the 50 HOXA locus following ASXL1 loss
and a modest increase in H3K4me3 at the
promoters of 50 HOXA genes with ASXL1 loss
[primer locations are shown in (A)].
(D) Similar ChIP for H3K27me3 followed by
qPCR across the HOXA locus in primary leu-
kemic blasts from two patients with ASXL1
mutations versus two without ASXL1 mutations
reveals H3K27me3 loss across the HOXA locus
in ASXL1 mutant cells.
(E) ChIP for EZH2 followed by qPCR at the 50 end
of HOXA locus in SET2 cells reveals loss of EZH2
enrichment with ASXL1 loss in SET2 cells. CHIP-
qPCR was performed in biologic duplicates and
ChIP-qPCR data is displayed as enrichment
relative to input. qPCR at the gene body of RRP1,
a region devoid of H3K4me3 or H3K27me3, is
utilized as a control locus.
The error bars represent standard deviation.
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2010). We therefore investigated the effects of combined
NRasG12D expression and Asxl1 loss in vivo. To do this, we
expressed NRasG12D in combination with an empty vector
expressing GFP alone or one of two different Asxl1 shRNA
constructs in whole bone marrow cells and transplanted theseCancer Cell 22, 180–193cells into lethally irradiated recipient
mice. We validated our ability to effec-
tively knock down ASXL1 in vivo by per-
forming qRT-PCR in hematopoietic cells
from recipient mice (Figure 7A and Fig-
ure S6A). Consistent with our in vitro
data implicating the HoxA cluster as an
ASXL1 target locus, we noted a marked
increase in HoxA9 and HoxA10 expres-
sion in bone marrow nucleated cells
from mice expressing NRasG12D in
combinationwith Asxl1 shRNAcompared
to mice expressing NRasG12D alone
(Figure 7B).
Expression of oncogenic NRasG12D
and an empty shRNA vector control led
to a progressive myeloproliferative
disorder as previously described (MacK-
enzie et al., 1999). In contrast, expression
of NRasG12D in combination with vali-
dated mASXL1 knockdown vectors re-sulted in accelerated myeloproliferation and impaired survival
compared with mice transplanted with NRasG12D/EV (median
survival 0.8 month for ASXL1 shRNA versus 3 months for control
shRNA vector: p < 0.005; Figure 7C) We also noted impaired
survival with an independent mASXL1 shRNA construct (p <
0.01; Figure S6B) Mice transplanted with NRasG12D/Asxl1, August 14, 2012 ª2012 Elsevier Inc. 187
Figure 6. ASXL1 Interacts with the PRC2 in Hematopoietic Cells
(A) Physical interaction between ASXL1 and EZH2 is demonstrated by transient transfection of HEK293T cells with FLAG-hASXL1 cDNA with or without hEZH2
cDNA followed by immunoprecipitation (IP) of FLAG epitope and western blotting for EZH2 and ASXL1.
(B) HEK293T cells were transiently transfected with FLAG-hASXL1 cDNA followed by IP of FLAG epitope and western blotting for SUZ12 and ASXL1. Endog-
enous interaction of ASXL1 with PRC2members was also demonstrated by IP of endogenous EZH2 and ASXL1 followed by western blotting of the other proteins
in whole cell lysates from SET2 cells.
(C) Lysates from the experiment shown in (B) were treated with benzonase to ensure nucleic acid free conditions in the lysates prior to IP as shown by ethidium
bromide staining of an agarose gel before and after benzonase treatment. IP of endogenous EZH2 and embryonic ectoderm development (EED) in a panel of
ASXL1-wild-type and mutant human leukemia cells reveals a specific interaction between ASXL1 and PRC2 members in ASXL1-wildype human myeloid
leukemia cells. In contrast, IP of the PRC1 member BMI1 failed to pull down ASXL1.
See also Figure S5.
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compared with NRasG12D/EV transplanted mice (Figures 7D
and 7E; Figure S6C). Histological analysis revealed a significant
increase in myeloid infiltration of the spleen and livers of
mice transplanted with NRasG12D/Asxl1 shRNA (Figure S6D).
Mice transplanted with NRasG12D/Asxl1 shRNA, but not
NRasG12D/EV, experienced progressive, severe anemia (Fig-
ure 7F). It has previously been identified that expression of onco-
genic K/N-Ras in multiple models of human/murine hematopoi-
etic systems results in alterations in the erythroid compartment
(Braun et al., 2006; Darley et al., 1997; Zhang et al., 2003). We
noted an expansion of CD71high/Ter119high erythroblasts in the
bonemarrow ofmice transplantedwithNRasG12D/Asxl1 shRNA
compared with NRasG12D/EV mice (Figure S6E). We also noted
increased granulocytic expansion in mice engrafted with
NRasG12D/Asxl1 shRNA positive cells, as shown by the pres-
ence of increased neutrophils in the peripheral blood (FigureS6D)
and the expansion of Gr1/Mac1 double-positive cells in the bone
marrow by flow cytometry (Figure S6F).
Previous studies have shown that hematopoietic cells from
mice expressing oncogenic Ras alleles or other mutations that
activate kinase signaling pathways do not exhibit increased
self-renewal in colony replating assays (Braun et al., 2004;
MacKenzie et al., 1999). This is in contrast to the immortalization
of hematopoietic cells in vitro seen with expression of MLL-AF9188 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.(Somervaille and Cleary, 2006) or deletion of Tet2 (Moran-Crusio
et al., 2011). Bone marrow cells from mice with combined over-
expression of NRasG12D plus Asxl1 knockdown had increased
serial replating (to five passages) compared to bone marrow
cells from mice engrafted with NRasG12D/EV cells (Figure 7G).
These studies demonstrate that Asxl1 loss cooperates with
oncogenic NRasG12D in vivo.
DISCUSSION
The data presented here identify that ASXL1 loss in hematopoi-
etic cells results in reduced H3K27me3 occupancy through inhi-
bition of PRC2 recruitment to specific oncogenic target loci.
Recent studies have demonstrated that genetic alterations in
the PRC2 complex occur in a spectrum of human malignancies
(Bracken and Helin, 2009; Margueron and Reinberg, 2011;
Sauvageau and Sauvageau, 2010). Activating mutations and
overexpression of EZH2 occur most commonly in epithelial
malignancies and in lymphoid malignancies (Morin et al., 2010;
Varambally et al., 2002). However, there are increasing genetic
data implicatingmutations that impair PRC2 function in the path-
ogenesis of myeloid malignancies. These include the loss-of-
function mutations in EZH2 (Abdel-Wahab et al., 2011; Ernst
et al., 2010; Nikoloski et al., 2010) and less common somatic
loss-of-function mutations in SUZ12, EED, and JARID2 (Score
Figure 7. Asxl1 Silencing Cooperates with
NRasG12D In Vivo
(A) Retroviral bone marrow transplantation of
NRasG12D with or without an shRNA for Asxl1
resulted in decreased Asxl1 mRNA expression as
shown by qRT-PCR results in nucleated peripheral
blood cells from transplanted mice at 14 days
following transplant.
(B) qRT-PCR revealed an increased expression
of HOXA9 and HOXA10 but not MEIS1 in the
bone marrow of mice sacrificed 19 days following
transplantation.
(C) Transplantation of bone marrow cells bear-
ing overexpression of NRasG12D in combination
with downregulation of Asxl1 led to a significant
hastening of death compared to mice transplanted
with NRasG12D/EV.
(D–F) Mice transplanted with NRasG12D/ASXL1
shRNA experienced increased splenomegaly (D)
and hepatomegaly (E), and progressive anemia
(F) compared with mice transplanted with
NRasG12D + an empty vector (EV).
(G) Bone marrow cells from mice with combined
NRasG12D overexpression/Asxl1 knockdown re-
vealed increased serial replating compared with
cells from NRasG12D/EV mice. Error bars repre-
sent standard deviation relative to control. Asterisk
indicates p < 0.05 (two-tailed, Mann Whitney
U test).
See also Figure S6.
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lodysplastic syndrome, and chronic myelomonocytic leukemia.
The data from genetically-engineered mice also support this
concept with Ezh2 overexpression models, revealing evidence
of promotion of malignant transformation (Herrera-Merchan
et al., 2012), and recent studies demonstrate a role for Ezh2
loss in leukemogenesis (Simon et al., 2012). Thus, it appears
that alterations in normal PRC2 activity and/or H3K27me3 abun-
dance in either direction may promote malignant transformation.
Our data implicate ASXL1 mutations as an additional genetic
alteration that leads to impaired PRC2 function in patients withCancer Cell 22, 180–19myeloid malignancies. In many cases,
patients present with concomitant
heterozygous mutations in multiple
PRC2 members or in EZH2 and ASXL1;
these data suggest that haploinsuffi-
ciency for multiple genes that regulate
PRC2 function can cooperate in hemato-
poietic transformation through additive
alterations in PRC2 function.
Many studies have investigated how
mammalian PcG proteins are recruited
to chromatin in order to repress gene
transcription and specify cell fate in
different tissue contexts. Recent in silico
analysis suggested that ASXL proteins
found in animals contain a number of
domains that likely serve in the recruit-
ment of chromatin modulators and tran-
scriptional effectors to DNA (Aravind andIyer, 2012). Data from ChIP and co-immunoprecipita-
tion experiments presented here suggest a specific role for
ASXL1 in epigenetic regulation of gene expression by facilitating
PRC2-mediated transcriptional repression of known leukemic
oncogenes. Thus, ASXL1may serve as a scaffold for recruitment
of the PRC2 complex to specific loci in hematopoietic cells, as
has been demonstrated for JARID2 in embryonic stem cells
(Landeira et al., 2010; Pasini et al., 2010; Peng et al., 2009;
Shen et al., 2009).
Recent data suggested that ASXL1 might interact with BAP1
to form a H2AK119 deubiquitanase (Scheuermann et al., 2010).3, August 14, 2012 ª2012 Elsevier Inc. 189
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independent alterations in chromatin state and gene expression
in hematopoietic cells. These data are consonant with recent
genetic studies, which have shown that germline loss of BAP1
increases susceptibility to uveal melanoma and mesothelioma
(Testa et al., 2011; Wiesner et al., 2011). In contrast, germline
loss of ASXL1 is seen in the developmental disorder Bohring-
Opitz Syndrome (Hoischen et al., 2011), but has not, to date,
been observed as a germline solid tumor susceptibility locus.
Whether alterations in H2AK119 deubiquitanase function due
to alterations in BAP1 and/or ASXL1 can contribute to leukemo-
genesis or to the pathogenesis of other malignancies remains to
be determined.
Integration of gene expression and chromatin state data
following ASXL1 loss identified specific loci with a known role
in leukemogenesis that are altered in the setting of ASXL1muta-
tions. These include the posterior HOXA cluster, including
HOXA9, which has a known role in hematopoietic transforma-
tion. We demonstrate that ASXL1 normally serves to tightly regu-
late HOXA gene expression in hematopoietic cells, and that loss
of ASXL1 leads to disorderedHOXA gene expression in vitro and
in vivo. Overexpression of 50 HOXA genes is a well-described
oncogenic event in hematopoietic malignancies (Lawrence
et al., 1996), and previous studies have shown thatHOXA9 over-
expression leads to transformation in vitro and in vivo when
co-expressed with MEIS1 (Kroon et al., 1998). Interestingly,
ASXL1 loss was not associated with an increase in MEIS1
expression, suggesting that transformation by ASXL1mutations
requires the co-occurrence of oncogenic disease alleles which
dysregulate additional target loci. These data and our in vivo
studies suggest that ASXL1 loss, in combination with co-occurr-
ing oncogenes, can lead to hematopoietic transformation and
increased self-renewal. Further studies in mice expressing
ASXL1 shRNA or with conditional deletion of Asxl1 alone and
in concert with leukemogeneic disease alleles will provide addi-
tional insight into the role of ASXL1 loss in hematopoietic stem/
progenitor function and in leukemogenesis.
Given that somatic mutations in chromatin modifying enzymes
(Dalgliesh et al., 2010), DNAmethyltransferases (Ley et al., 2010),
and other genes implicated in epigenetic regulation occur
commonly in human cancers, it will be important to use epige-
nomic platforms to elucidate how these disease alleles con-
tribute to oncogenesis in different contexts. The data here
demonstrate how integrated epigenetic and functional studies
can be used to elucidate the function of somatic mutations in
epigenetic modifiers. In addition, it is likely that many known
oncogenes and tumor suppressors contribute, at least in part,
to transformation through direct or indirect alterations in the
epigenetic state (Dawson et al., 2009). Subsequent epigenomic
studies of human malignancies will likely uncover novel routes
to malignant transformation in different malignancies, and thera-
peutic strategies that reverse epigenetic alterations may be of
specific benefit in patientswithmutations in epigeneticmodifiers.EXPERIMENTAL PROCEDURES
Cell Culture
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and nonessential amino190 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.acids. Human leukemia cell lines were cultured in RPMI-1640 medium supple-
mented with 10% FBS+1 mM hydrocortisone+10% horse serum (UKE1 cells),
RPMI-1640 supplemented with 10% FBS (K562, MOLM13, KCL22, KU812
cells), RPMI-1640 supplemented with 20% FBS (SET2, NOMO1, Monomac-6
cells), or IMDM+20%FBS (KBM5 cells). For proliferation studies, 13 103 cells
were seeded in 1ml volume of media in triplicate and cell number was counted
manually daily for 7 days by Trypan blue exclusion.
Plasmid Constructs, Mutagenesis Protocol, Short Hairpin RNA, and
Small Interfering RNA
See Supplemental Information.
Primary Acute Myeloid Leukemia Patient Samples and ASXL1,
BAP1, EZH2, SUZ12, and EED Genomic DNA Sequencing Analysis
Approval was obtained from the institutional review boards at Memorial Sloan-
Kettering Cancer Center and at the Hospital of the University of Pennsylvania
for these studies, and informed consent was provided according to the Decla-
ration of Helsinki. Please see Supplemental Information for details on DNA
sequence analysis.
Western Blot and Immunoprecipitation Analysis
Western blots were carried out using the following antibodies: ASXL1 (Clone
N-13; Santa Cruz (sc-85283); N-terminus directed), ASXL1 (Clone 2049C2a;
Santa Cruz (sc-81053); C terminus directed), BAP1 [clone 3C11; Santa Cruz
(sc-13576)], BMI1 (Abcam ab14389), EED (Abcam ab4469), EZH2 (Active
Motif 39933 or Millipore 07-689), FLAG (M2 FLAG; Sigma A2220), Histone
H3 lysine 27 trimethyl (Abcam ab6002), Histone H2A Antibody II (Cell
Signaling Technologies 2578), Ubiquityl-Histone H2AK119 (Clone D27C4;
Cell Signaling Technologies 8240), RING1A (Abcam ab32807), SUZ12 (Abcam
ab12073), and total histone H3 (Abcam ab1791), and tubulin (Sigma, T9026).
Antibodies different from the above used for immunoprecipitation include:
ASXL1 [clone H105X; Santa Cruz (sc-98302)], FLAG (Novus Biological
Products; NBP1-06712), and EZH2 (Active Motif 39901). Immunoprecipitation
and pull-down reactions were performed in an immunoprecipitation buffer
(150 mM NaCl, 20 mM Tris (pH 7.4–7.5), 5 mM EDTA, 1% Triton, 100 mM
sodium orthovanadate, protease arrest (Genotec), 1 mM PMSF, and phenyl-
arsene oxide). To ensure nuclease-free immunoprecipitation conditions,
immunoprecipitations were also performed using the following methodology
(Muntean et al., 2010): cells were lysed in BC-300 buffer (20 mM Tris-
HCl (pH 7.4), 10% glycerol, 300 mM KCl, 0.1% NP-40) and the cleared lysate
was separated from the insoluble pellet and treated with MgCl2 to 2.5 mM and
benzonase (Emanuel Merck, Darmstadt) at a concentration of 1,250 U/ml. The
lysate was then incubated for 1–1.5 hr at 4. The reaction was then stopped
with addition of 5 mM EDTA. DNA digestion is confirmed on an ethidium
bromide agarose gel. We then set up our immunoprecipitation by incubating
our lysate overnight at 4.
Histone Extraction and Histone LC/MS Analysis
See Supplemental Information.
Gene Expression Analysis
Total RNA was extracted from cells using QIAGEN’s RNeasy Plus Mini kit
(Valencia, CA, USA). cDNA synthesis, labeling, hybridization, and quality
control were carried out as previously described (Figueroa et al., 2008). Ten
micrograms of RNA was then used for generation of labeled cRNA according
to the manufacturer’s instructions (Affymetrix, Santa Clara, CA, USA). Hybrid-
ization of the labeled cRNA fragments and washing, staining, and scanning of
the arrays were carried out as per instructions of the manufacturer. Labeled
cRNA from CD34+ cells treated with either ASXL1 siRNA or controls were
analyzed using the Affymetrix HG-U133-Plus2.0 platform and from UKE1 cells
using the Illumina Href8 array. All expression profile experiments were carried
out using biological duplicates. ‘‘Present’’ calls in R80% of samples were
captured and quantile normalized across all samples on a per-chip basis.
Raw expression values generated by Genome Studio (Illumina) were filtered
to exclude probesets having expression values below negative background
in R80% of samples. Probesets remaining after background filtering were
log-2 transformed and quantile normalized on a per-chip basis. qRT-PCR
was performed on cDNA using SYBR green quantification in an ABI 7500
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ASXL1 Loss Inhibits PRC2 in Myeloid Leukemiasequence detection system. The sequences of all qRT-PCR primers are listed
in the Supplemental Information.
Chromatin Immunoprecipitation and Antibodies
ChIP experiments for H3K4me3, H3K27me3, and H3K36me3 were carried
out as described previously (Bernstein et al., 2006; Mikkelsen et al., 2007).
Cells were cross-linked in 1% formaldehyde, lysed, and sonicated with
a Branson 250 Sonifier to obtain chromatin fragments in a size range
between 200 and 700 bp. Solubilized chromatin was diluted in ChIP dilution
buffer (1:10) and incubated with antibody overnight at 4C. Protein A
sepharose beads (Sigma) were used to capture the antibody-chromatin
complex and washed with low salt, LiCl, as well as TE (pH 8.0) wash
buffers. Enriched chromatin fragments were eluted at 65C for 10 min, sub-
jected to cross-link reversal at 65C for 5 hr, and treated with Proteinase K
(1 mg/ml), before being extracted by phenol-chloroform-isoamyl alcohol, and
ethanol precipitated. ChIP DNA was then quantified by QuantiT Picogreen
dsDNA Assay kit (Invitrogen). ChIP experiments for ASXL1 were carried
out on nuclear preps. Cross-linked cells were incubated in swelling buffer
(0.1 M Tris pH 7.6, 10 mM KOAc, 15 mM MgOAc, 1% NP40), on ice for
20 minutes, passed through a 16G needle 20 times and centrifuged to
collect nuclei. Isolated nuclei were then lysed, sonicated, and immu-
noprecipitated as described above. Antibodies used for ChIP include
anti-H3K4me3 (Abcam ab8580), anti-H3K27me3 (Upstate 07-449), anti-
H3K36me3 (Abcam ab9050), and anti-ASXL1 [clone H105X; Santa Cruz
(sc-98302)], and Ubiquityl-Histone H2AK119 (Clone D27C4; Cell Signaling
Technologies 8240).
Sequencing Library Preparation, Illumina/Solexa Sequencing, and
Read Alignment and Generation of Density Maps
See Supplemental Information.
HOXA Nanostring nCounter Gene Expression CodeSet
Direct digital mRNA analysis of HOXA cluster gene expression was performed
using a Custom CodeSet including each HOXA gene (NanoString Technolo-
gies). Synthesis of the oligonucleotides was done by NanoString Technolo-
gies, and hybridization and analysis were done using the Prep Station and
Digital Analyzer purchased from the company.
Animal Use, Retroviral Bone Marrow Transplantation, Flow
Cytometry, and Colony Assays
Animal care was in strict compliance with institutional guidelines established
by the Memorial Sloan-Kettering Cancer Center, the National Academy
of Sciences Guide for the Care and Use of Laboratory Animals, and the
Association for Assessment and Accreditation of Laboratory Animal Care
International. All animal procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) at Memorial Sloan-Kettering
Cancer Center. See Supplemental Information for more details on animal
experiments.
Statistical Analysis
Statistical significance was determined by the Mann-Whitney U test and
Fisher’s exact test using Prism GraphPad software. Significance of survival
differences was calculated using Log-rank (Mantel-Cox) test. p < 0.05 was
considered statistically significant. Normalized expression data from CD34+
cord blood was used as a Gene Set Enrichment Analysis query of the C2 data-
base (MSig DB) where 1,000 permutations of the genes was used to generate
a null distribution. A pre-ranked gene list, containing genes upregulated at
least log2 0.5-fold, in which the highest ranked genes corresponds to the
genes, with the largest fold-difference between Asxl1 hairpin-treated UKE1
cells and those treated with empty vector, was used to query the C2 MSig
DB as described above.
ACCESSION NUMBERS
All microarray data used in this manuscript are deposited in Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under GEO accession number
GSE38692. The ChIP-Seq data are deposited under GEO accession number
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